ASCO: Vepdegestrant ups survival in ER+, HER2− advanced breast cancer with ESR1 mutations

Published Date: 03 Jun 2025

For patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer, the oral proteolysis-targeting chimera ER degrader, vepdegestrant, leads to significantly ...

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Except for Black Patients, the Rates of Gallbladder Cancer Are Stable or Declining.

2.

The risk of ovarian cancer is not increased by salpingectomy, according to JAMA.

3.

Ivonescimab Tops Pembrolizumab in PD-L1-Positive, Advanced NSCLC

4.

Rising rates of head and neck cancers in England

5.

Recent Rise in Early-Onset Solid Tumors Is Associated with Accelerated Aging.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot